Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review Read more
UK Grants Full Marketing Authorization to Karyopharm and Menarini Group’s NEXPOVIO for Multiple Myeloma Treatment Read more
FDA has granted fast track designation to Biohaven’s Taldefgrobep Alfa for the treatment of spinal muscular atrophy Read more
Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China Read more
Capricor Therapeutics and Nippon Shinyaku Form Partnership for CAP-1002 Distribution in Japan, Treating Duchenne Muscular Dystrophy Read more
M2GEN and Zephyr AI Collaborate to Advance Cancer Treatment and Cure Discovery for Patients Read more
SYFOVRE (Pegcetacoplan Injection) Approved by FDA as the First and Only Treatment for Leading Cause of Blindness, Geographic Atrophy (GA) Read more
Teva Announces FDA Approval of AUSTEDO XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO (deutetrabenazine) Tablets Read more